Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis

NCT03738397 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03738397
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03738397 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
February 21, 2019
Completion date
December 9, 2020
Enrollment
673 (actual)
Sites
159

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis